Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden
Authors' conclusion
Omnipod 5 was found to offer superior value compared with MDI, showing cost-effectiveness for adults with type 1 diabetes in Sweden with better patient outcomes and fewer complications.
Study context
- Population
- Adults with T1D in Sweden (modelled; treatment effects from the RADIANT RCT)
- Comparison
- Omnipod 5 AID system vs multiple daily injections (MDI) with CGM
- Outcome
- Incremental costs, life expectancy, QALY and incremental cost-utility ratios (ICURs)
- Follow-up
- 50-year time horizon
Methodological detailsIQVIA Core Diabetes Model (version 10.0), payer perspective, 50-year time horizon, sensitivity analysis
- IQVIA Core Diabetes Model (version 10.0)
- Payer perspective
- 50-year time horizon
- Sensitivity analysis
Main finding
As reported in the abstract
Cost-effectiveness (ICUR) of Omnipod 5 vs MDI
ICUR, direct costs only
201 161 SEK per QALY
ICUR, combined costs
179 247 SEK per QALY
Additional quality-adjusted life-years (QALY) with Omnipod 5 (base case)
3.82
Omnipod 5 cost-effective in base case and sensitivity analyses; Incremental cost-utility ratios (ICURs) below willingness-to-pay threshold
500 000 SEK per QALY
Original publication
Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden. Diabetes Obes Metab. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →